Zabadinostat clinical trials
Its developmentBy ImmunityBio and Celleron Therapeutics, step by step2 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses zabadinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Stephen Chan Lam (1) · Oxford University Hospitals NHS Trust (1) · Celleron Therapeutics Ltd. (1) · ImmunityBio, Inc. (1) · University College, London (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (1) · Sotevtamab (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1)
Related medicines
As reviewed, each with the page that says it.
- One of HDAC inhibitors source
Studies
Open first, then newest update. How each study uses zabadinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerWithdrawnPhase 1ImmunityBio, Inc.NCT07488884Written as Zabadinostat (CXD101)How we know
- CXD101 in Immunotherapy-related Liver CancerActive, not recruitingPhase 2Stephen Chan LamNCT05873244Written as Zabadinostat (CXD101) and GeptanolimabHow we know
- Phase 1 Trial of CXD101 in Patients With Advanced CancerCompletedPhase 1Oxford University Hospitals NHS TrustNCT01977638Written as CXD101How we know
- A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnPhase 1/2University College, LondonNCT03873025Written as Pembrolizumab and CXD101How we know
- A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal CancerStatus unknownPhase 1/2Celleron Therapeutics Ltd.NCT03993626Written as CXD101 in Combination With NivolumabHow we know
Codes
What other systems call zabadinostat · ClinicalTrials.gg INT015123
- UNII (FDA) 5TNV87ICD2ZABADINOSTATConfirmed FDA, Wikidata
- Wikidata Q119852211zabadinostatConfirmed FDA, Wikidata
- NCI Thesaurus C112177ZabadinostatOne source FDA
- DrugBank DB16182One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5TNV87ICD2 | ZABADINOSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q119852211 | zabadinostat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C112177 | Zabadinostat | One source FDA |
| DrugBank | DB16182 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.